Our Management Team consists of proven, experienced leaders who are committed to focusing on People and on Therapies and Developing long-term relationships with our customers.
Dror Chevion is our Chief Executive Officer.
Mr. Chevion is a successful Serial Entrepreneur with over 25 years of global experience in several industries. Earlier in his career, Mr. Chevion completed his BA in economics and business at the Hebrew University, Jerusalem and then began working for the Israeli Ministry of Finance, Department of the Budget. Mr. Chevion then continued to the private sector where he has held executive positions including VP Finance, VP Business Development, CEO, Managing Director, and Board Member. In addition, Mr. Chevion has served as Board Member in 2 publicly traded companies on the Tel-Aviv Stock Exchange. Mr. Chevion has an MBA from a joint program by J. L. Kellogg School of Management (Chicago, USA) and the Tel-Aviv University (Israel).
Prof. Mordechai (Mottie) Chevion is our Chief Scientific Officer.
Mordechai “Mottie” Chevion, professor of biochemistry and incumbent of the Dr. William Ganz Chair of Heart Studies, has formal university training in Chemistry and Physics (B.Sc.), Physical Chemistry (M.Sc.), and Pharmaceutical Chemistry (Ph.D.). His past research projects have focused on the mechanism of food-induced hemolytic crisis in G-6-PD deficiency (Favism), and the role of transition metals in biologically injurious processes involving free radicals. Prof. Chevion has also investigated the burn related injurious processes induced to the skin and eye tissues by toxic chemicals including warfare agents. Recently he focused on novel mechanisms of protection of the ischemic heart, brain, retina and intestine. These studies have been extended to the diabetic heart.
Through his research, Prof. Chevion has developed new drugs—currently being developed for clinical application—and novel modalities to counteract tissue injury mediated by free radicals. These drugs proved highly effective against inflammatory and other diseases.
Over the years, Prof. Chevion has edited and published two books, over one hundred and sixty fully refereed scientific papers, more than 400 abstracts and short papers, and invented 10 patents concerning antioxidant drugs.
In addition to his intensive academic activities, Prof. Chevion has been involved in establishing pioneering relationships and promoting cooperative activities with foreign (mainly Asian) governments, universities and research institutions. For his successful activities, Prof. Chevion was nominated for the King Boudoin International Development Prize in 1994. Prof. Chevion served as a consultant for the major corporations in Israel and other countries.
Dr. Susan Alpert, M.D., Ph.D. is our Regulatory Lead.
Dr. Alpert has served as Executive Vice President of Regulatory Affairs, Exalenz Bioscience Ltd, Senior Advisor at Accelmed Fund. She served as Regulatory Consultant and Chief Regulatory Officer at Accelmed Fund. She serves as a Member of the Scientific Advisory Team at Cellect Biomed Ltd. Dr. Alpert serves as an Advisor of VGBio, Inc. She is Executive in Residence at the Medical Industry Leadership Institute at the Carlson School at the University of MN. She served as Executive Vice President of Regulatory Affairs at Exalenz Bioscience Ltd and served as its Senior Vice President of Regulatory Affairs since November 2011. Dr. Alpert served as Chief Quality & Regulatory Officer and Vice President at Medtronic MiniMed, Inc. since May 2004. She served as Chief Regulatory Officer of Medtronic plc since May 2008 and its Senior Vice President of Global Regulatory Affairs/Senior Vice President from November 2005 to May 2011. Dr. Alpert was responsible for all Medtronic quality, regulatory, and clinical compliance efforts including overseeing health policy and payment. She served as Chief Quality & Regulatory Officer of Medtronic from May 2004 to November 2005 and as its Vice President from July 2003 to November 2005. She joined Medtronic in July 2003. She served as Vice President of Regulatory Sciences at CR Bard Inc. from October 2000 to July 2003 and also served as its Senior Vice President of Regulatory. Before joining Bard, Dr. Alpert served at the FDA where she held a variety of positions in the Centers dealing with drugs, devices, and radiological health, and foods from June 1987 to August 2000, including six years as the Director of the Office of Device Evaluation. She serves on the board of the Food Drug Law Institute (FDLI). Dr. Alpert is a Director of the Medical Technology Leadership Forum (MTLF). In addition, she is a Director of the Women Business Leaders (WBL). She has served as the Director of Medical Device Assessment in the FDA. She is a microbiologist and pediatrician with a specialty in infectious diseases and has practical experience in laboratory research and clinical trials. Dr. Alpert holds an M.S. and Ph.D. in Biomedical Sciences from New York University. She received her M.D. from the University of Miami and completed her clinical training at Montefiore Medical Center and at Children's National Medical Center. She completed her undergraduate degree at Barnard College, Columbia University.